1. Class action filed against Cardlytics for misleading investors. 2. Key allegations include failure to disclose risks of revenue decline. 3. Q2 2024 revenue dropped 9%, triggering a 57.1% stock price drop. 4. CEO resignation exacerbated negative investor sentiment. 5. Potential impacts on future stock performance due to legal issues.
The class action accusations and revenue decline indicate serious operational issues, reminiscent of other high-profile legal disputes that devastated stock prices in tech. Similar cases have shown prolonged downward trends in stock value following legal actions.
The legal issues surrounding CDLX are likely to impact its market perception and stock valuation significantly. Past similar lawsuits have led to long-lasting drops in affected companies' stock prices.
The class action could result in significant financial liabilities and ongoing negative publicity. Long-term reputational damage may ensue, affecting investor confidence and business operations.
Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Cardlytics, Inc. (NASDAQ: CDLX) securities between March 14, 2024 and August 7, 2024. Cardlytics operates an advertising platform in the U.S. and the U.K.
For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.
Robbins LLP is Investigating Allegations that Cardlytics, Inc. (CDLX) Misled Investors Regarding its Business Prospects
According to the complaint, during the class period, defendants failed to disclose to investors:
On August 7, 2024, Cardlytics released its second quarter 2024 financial results, revealing a 9% year-over-year decrease in revenue to $69.6 million, alongside a 3% decline in adjusted contribution to $36.4 million. Cardlytics also announced that its CEO had stepped down from the Board of Directors. On this news, the Company's stock price fell $3.94, or 57.1%, to close at $2.96 per share on August 8, 2024.
You may be eligible to participate in the class action against Cardlytics, Inc. Shareholders who want to serve as lead plaintiff for the class must file papers with the court by March 25, 2025. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.
All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002.
To be notified if a class action against Cardlytics, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.
Attorney Advertising. Past results do not guarantee a similar outcome.